Clinical Study

Randomized Double Blind Placebo Controlled Study Of Erlotinib Or Placebo In Patients With Completely Resected Epidermal Growth Factor Receptor (Egfr) Mutant Non-Small Cell Lung Cancer (Nsclc)

Posted Date: Aug 17, 2017

  • Investigator: John Morris
  • Specialties: Thoracic Surgery, Hematology/Oncology, Oncology, Cancer, Lung Cancer
  • Type of Study: Drug

The purpose of this study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug). Researchers are trying to find out if the mutation called EGFR (Epidermal Growth Factor Receptor) could help make decisions about which type of treatment is best for people with this type of cancer. People not in a research study are usually not treated with anything after they finish their chemotherapy although some of them may receive radiation therapy.

Criteria:

To Be Eligible For This Study, Patients Must Have Early Stage Non-Small Cell Lung Cancer That Was Surgically Removed And May Have Been Treated With Chemotherapy And/Or Radiation.

Keywords:

A081105, Egfr, Non-Small Cell , Cancer, Lung

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com